Figure 1 | Scientific Reports

Figure 1

From: Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism

Figure 1

Development of parathyroid hormone (A), corrected calcium (B) and phosphate (C) among referred CKD patients in Stockholm, Sweden 2006–2012 before and after Cinacalcet initiation. Below figure: Parathyroid hormone levels (PTH) in ng/L with 95% confidence interval. M(month). Negative signs indicate that the month is prior to treatment initiation and positive numbers that the month is after the treatment initiation.

Back to article page